Bernstein, Harold S.

Botvinick, Elias H

Boushey, Homer A

Broaddus, V Courtney

Brodsky, Frances M

Bruneau, Benoit G

Caughey, George H

Chapman, Harold A

Charo, Israel F

Chatterjee, Kanu

Chuang, Pao-Tien

Clyman, Ronald I

Conklin, Bruce R

Conte, Michael S

Coughlin, Shaun R

Dobbs, Leland G

Engel, Joanne N

Fahy, John Vincent

Farese, Robert V

Fielding, Christopher J

Fineman, Jeffrey R

Gardner, David G

Gartner, Zev Jordan

Glantz, Stanton A

Gropper, Michael

Grossman, William

Hawgood, Samuel

Hoffman, Julien I

Ingraham, Holly A

Julius, David J

Karliner, Joel S

Kornberg, Thomas B

Kurtz, Theodore W

Lazarus, Stephen C

Mahley, Robert W

Malloy, Mary J.

Mann, Michael J

Matthay, Michael A

Mcdonald, Donald M

Mikawa, Takashi

Minor, Daniel L

Mostov, Keith E

Olgin, Jeffrey E

Pittet, Jean-Francois

Redberg, Rita F

Reiter, Jeremy F.

Rosen, Steven D

Rowitch, David H

Scheinman, Melvin M

Schiller, Nelson B

Shokat, Kevan M

Simpson, Paul C

Springer, Matthew L

Srivastava, Deepak

Stainier, Didier Y. R.

Teitel, David F

Von Zastrow, Mark E

Weiner, Orion D

Woodruff, Prescott G

Xu, Allison Wanting

Young, William L

CVRI Scientists

Paul C Simpson, M.D.
Prof In Rsdn

Research Interests:
Molecular & cellular mechanisms of myocardial hypertrophy and heart failure Adrenergic receptors, signaling, and drug development

Summary:
Dr. Simpson is working to develop new drugs to treat heart failure, one of the most common causes of hospitalization and death in the USA and Western World. He has recently identified a promising drug target, alpha-1-adrenergic receptors, and is working to translate this into clinical use.

CVRIHead